Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Trial Profile

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Anastrozole; Letrozole
  • Indications Advanced breast cancer; Carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2020 Results of exploratory analysis assessing correlation between CTC levels with response to pazopanib presented at the 43rd Annual San Antonio Breast Cancer Symposium.
    • 11 Jun 2020 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 Results assessing the clinical benefit (CB) of Pazopanib combined with nonsteroidal aromatase inhibitors (NSAIs) in patients with ABC resistant to NSAIs, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top